Early

Twenty-eighth Annual CONNECTIONS™ Conference Addresses Growth of Technology in Consumer and Business, Including Smart Home, Security, Health, and Entertainment

Retrieved on: 
Tuesday, May 7, 2024
Trident, Alarm.com, Sale, Networking hardware, EPB, Internet, Early, Ecosystem, Amazon Web Services, Advertising, AI, Verizon Communications, Silicon Labs, ADT, Generali, Imperial Capital, RapidSOS, Luigi, Cardinal Peak, SmartThings, Control, AWS, Artificial intelligence, Wyze, Television

DALLAS, May 7, 2024 /PRNewswire/ -- Parks Associates will feature key findings from its research Smart Home: Integration, Automation, and Control at the 28th annual CONNECTIONS™: The Premier Connected Home Conference, May 7-9 at the Hilton Dallas/Plano Granite Park Hotel in Plano, TX. The executive conference addresses the consumer and small to medium buyer journey for technology solutions.

Key Points: 
  • The executive conference addresses the consumer and small to medium buyer journey for technology solutions.
  • The firm's research shows spur-of-the-moment and experiential shopping are the top triggers for smart home device purchases.
  • Consumers have gaps in their daily activities where technology can help provide convenience, context, and valuable information.
  • Smart video doorbells are the most popular device, with 32% of US internet households planning to buy one in the next six months, followed by smart cameras, smart smoke/CO detectors, and smart lights.

Gallaudet University Awarded $3.75 Million to Create a National Implementation and Change Center for the Early Hearing Detection and Intervention Program

Retrieved on: 
Tuesday, April 16, 2024
MCHB, Education, American Academy, Intervention, HHS, Early, Hearing, Hands & Voices, Communication, Unitary state, Gallaudet University, Pediatrics (journal), Acquisition, National Network, HRSA, Mother, Government, Nursing

WASHINGTON, April 16, 2024 /PRNewswire/ -- Gallaudet University announced today that it has entered into a five-year, $3.75 million cooperative agreement with the Maternal and Child Health Bureau ( MCHB ) in the Health Resources and Services Administration ( HRSA ) to establish the new Implementation and Change Center within the Early Hearing Detection and Intervention (EHDI) National Network.

Key Points: 
  • WASHINGTON, April 16, 2024 /PRNewswire/ -- Gallaudet University announced today that it has entered into a five-year, $3.75 million cooperative agreement with the Maternal and Child Health Bureau ( MCHB ) in the Health Resources and Services Administration ( HRSA ) to establish the new Implementation and Change Center within the Early Hearing Detection and Intervention (EHDI) National Network.
  • Gallaudet University joins esteemed partners including Hands & Voices, serving as the Family Leadership in Language and Learning Center, and the American Academy of Pediatrics, serving as the Provider Education Center, in this collective effort.
  • The National Beacon Center will support EHDI programs throughout the United States, as well as the nation's system of services for deaf and hard of hearing children.
  • To learn more about Gallaudet University, please visit https://gallaudet.edu/ .

Saranas Reveals Groundbreaking SAFE-MCS Study Results at CRT 2024

Retrieved on: 
Monday, March 11, 2024
Surgery, Medical Devices, Health, Clinical Trials, Cardiology, CRT, Aortic stenosis, Physician, Risk, Early, Patient, Percutaneous coronary intervention, Henry Ford Health, MCS, PROTECT, Morristown Medical Center, Henry Ford, PCI, Bleeding, EVAR, Safety, Structural heart disease, TAVR, FDA

“This study is the first of its kind to specifically evaluate bleeding complications in patients undergoing protected PCI, with independently adjudicated results.

Key Points: 
  • “This study is the first of its kind to specifically evaluate bleeding complications in patients undergoing protected PCI, with independently adjudicated results.
  • The Saranas Early Bird Bleed Monitoring System is the first and only FDA-approved device for real-time monitoring of endovascular bleed complications.
  • “We would like to thank the excellent team of physicians and coordinators who contributed to the success of this study,” commented Mike MacKinnon, CEO and President of Saranas.
  • Saranas is dedicated to establishing a new benchmark for bleed detection during and after endovascular procedures, with the goal of improving patient outcomes and decreasing healthcare expenses overall.”

Trinity Biotech Announces Application for Early Sjogrens Syndrome Test Panel PLA Code

Retrieved on: 
Wednesday, February 7, 2024
CPT, Early, Arthralgia, Patient, Swelling, PLA, Risk, Pharmaceutical industry

(Nasdaq: TRIB) (the “Company”) today announced that its New York based reference laboratory, Immco Diagnostics, has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjögrens Syndrome Test Panel, to allow for an optimised market access strategy to deliver broader patient access and improved profitability.

Key Points: 
  • (Nasdaq: TRIB) (the “Company”) today announced that its New York based reference laboratory, Immco Diagnostics, has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjögrens Syndrome Test Panel, to allow for an optimised market access strategy to deliver broader patient access and improved profitability.
  • It is estimated that up to approximately 3 million people in the US have Sjögrens Syndrome, making it one of the most prevalent autoimmune syndromes.
  • The Early Sjögrens Syndrome Test Panel is a valuable immunological tool for clinicians to both identify patients earlier, when therapeutic intervention is most effective, and to also identify patient cohorts most at risk of progression to Sjögren’s Syndrome.
  • A PLA code is a distinct, specific code assigned to a particular test and approved by the American Medical Association’s (AMA) Current Procedural Terminology (CPT) Editorial Panel.

Calysta’s FeedKind Protein Receives MARA Approval for Use in Aquaculture Feeds

Retrieved on: 
Wednesday, January 31, 2024
Biotechnology, Retail, Health, Consumer, Other Science, Environment, Sustainability, Agriculture, Natural Resources, Fitness & Nutrition, Science, Veterinary, Food, Beverage, Pets, Fermentation, Research, Early, Salmon, Weather, Protein, Methane, Aquaculture

Calysta’s FeedKind® protein has received formal approval for use in aquaculture feeds in China as the company’s joint venture with Adisseo, Calysseo, prepares to deliver first product to customers through Adisseo sales network in China.

Key Points: 
  • Calysta’s FeedKind® protein has received formal approval for use in aquaculture feeds in China as the company’s joint venture with Adisseo, Calysseo, prepares to deliver first product to customers through Adisseo sales network in China.
  • The country’s Ministry of Agriculture and Rural Affairs (MARA) has formally given Calysta’s single cell protein full approval for use in fish and shrimp feeds after an extensive evaluation process.
  • It means that protein produced by Calysseo – Calysta and Adisseo’s joint venture to produce FeedKind for the Asian aquaculture market – can now be sold and used in Chinese aquaculture feeds.
  • Calysseo’s first production plant is in Chongqing, already producing sustainable FeedKind protein for the aquaculture industry, giving producers access to an alternative to plant or animal sources for aquafeed diets.

The ABCs of Financial Crime: Consumer Education is the First Line of Defense

Retrieved on: 
Tuesday, January 30, 2024
Partnership, Nature, Coffee, Multimedia, Ageing, Crime, Research, Fear, DNA, Fraud, FINRA, Early, Silver, Retirement, Safety, Early warning, Investment, Love, Social media, FTC, Vox Media, Better Business Bureau, Education, National Council, EMV, Cryptocurrency

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Criminals have been challenging the banking and digital payments space for decades. As the financial services industry began offering safeguards like EMV chips, 3Dsecure, and biometrics, at Early Warning we've seen criminals pivot to new strategies, leveraging their technology know-how and preying on the weakest link of all -- human nature.

Key Points: 
  • Thanks to social media and many other channels, it is now easier than ever to tailor crimes to appeal to consumer emotions.
  • In 'pay yourself' scams, a criminal sends a text or call impersonating your bank or credit union.
  • Our Zelle® consumer education efforts started over five years ago with a partnership promoting financial literacy with high school students.
  • Over the years, our efforts evolved to include additional partnerships to reach broader audiences and expand resources on our website within the Financial Education Center.

Alzheon CEO Dr. Martin Tolar to Present ALZ-801/Valiltramiprosate Investigational Oral Alzheimer’s Treatment Program at Nobel Forum at Karolinska Institute in Stockholm, Sweden

Retrieved on: 
Wednesday, January 3, 2024
Science, Neurology, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Karolinska Institute, Cognition, Cerebrospinal fluid, Implementation, Risk, Cerebral edema, MD, Doctor of Philosophy, Nerve, Early, Neurotoxicity, Amyloid, Patient, Safety, Therapy, Pharmaceutical industry

Alzheon Founder, President, and CEO, Martin Tolar, MD, PhD, will present an overview of investigational oral ALZ-801/valiltramiprosate anti-amyloid oligomer treatment program in the section “Optimal Treatment for Future – Combination Therapy?” moderated by Kaj Blennow, MD, PhD, on January 19 at 1:30 PM CET (7:30 AM EST).

Key Points: 
  • Alzheon Founder, President, and CEO, Martin Tolar, MD, PhD, will present an overview of investigational oral ALZ-801/valiltramiprosate anti-amyloid oligomer treatment program in the section “Optimal Treatment for Future – Combination Therapy?” moderated by Kaj Blennow, MD, PhD, on January 19 at 1:30 PM CET (7:30 AM EST).
  • “We are honored to have received an invitation to present at the prestigious Nobel Forum and discuss how ALZ-801 tablet could help shape the future therapeutic landscape for Alzheimer’s disease.
  • Alzheon's simplified approach with an oral tablet has an opportunity to transform the standard of care for millions of patients,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.
  • “ALZ-801 efficacy data and a favorable safety profile, showing no increased risk of vasogenic edema, underscore the differentiated clinical profile of the treatment.

Alzheon CEO Dr. Martin Tolar to Discuss Positive Results from Phase 2 Biomarker Study and Upcoming Readout from Pivotal APOLLOE4 Phase 3 Study Evaluating Oral ALZ-801/Valiltramiprosate at Truist Securities BioPharma Symposium

Retrieved on: 
Tuesday, October 31, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Amyloid, Czech Institute For International Meetings, AD, Ageing, Plaque, Organic chemistry, CSF, APOE4, MD, Symposium, Genotype, Doctor of Philosophy, Lotte New York Palace Hotel, Cerebrospinal fluid, Truist, Early, Risk, NDA, Safety, Patient, Neurotoxicity, Pharmaceutical industry, Alzheon

Alzheon executive management will be available to meet with qualified members of the investor community who are registered to attend the conference.

Key Points: 
  • Alzheon executive management will be available to meet with qualified members of the investor community who are registered to attend the conference.
  • This panel will be moderated by Truist analyst, Robyn Karnauskas, PhD.
  • “Alzheon’s simple oral tablet has the potential to address a large unmet need from both an access and treatment perspective.
  • In addition, Alzheon is collaborating with the Czech Institute of Organic Chemistry & Biochemistry (IOCB) to develop an assay to measure neurotoxic amyloid oligomers in CSF.

BUILD-A-BEAR'S NEW HOLIDAY FILM 'GLISTEN AND THE MERRY MISSION' OPENS THIS WEEKEND IN THEATERS

Retrieved on: 
Friday, November 3, 2023
Build-A-Bear Workshop, Awe, Early, NYSE, Glistening-green tanager, Parent, Film industry, Cinemark Theatres

ST. LOUIS, Nov. 3, 2023 /PRNewswire/ -- The much anticipated, new animated holiday film by Build-A-Bear Workshop, Inc. (NYSE: BBW), is now playing at select Cinemark theaters. Build-A-Bear recently hosted a private showing of the movie in St. Louis to kick off this weekend's theatrical release, and the feedback from kids and parents alike is overwhelmingly positive and included laughing, smiles, gasping and applause. Early reviews of the movie note its charm and good cheer, as Glisten and the Merry Mission is on its way to becoming one of the season's favorite holiday movies for families.

Key Points: 
  • Viewers at Early Showing Share Smiles, Giggles and Awe for Brand's New Holiday Movie, In Theaters Now for a Limited Time
    ST. LOUIS, Nov. 3, 2023 /PRNewswire/ -- The much anticipated, new animated holiday film by Build-A-Bear Workshop, Inc. (NYSE: BBW), is now playing at select Cinemark theaters.
  • Build-A-Bear recently hosted a private showing of the movie in St. Louis to kick off this weekend's theatrical release, and the feedback from kids and parents alike is overwhelmingly positive and included laughing, smiles, gasping and applause.
  • Early reviews of the movie note its charm and good cheer, as Glisten and the Merry Mission is on its way to becoming one of the season's favorite holiday movies for families.
  • Glisten and the Merry Mission is now playing at select Cinemark theaters across the U.S. Tickets are now available for purchase by visiting Cinemark.com and on the Cinemark app.

Lung Cancer Mutation Consortium LEADER Trial Enrolls 100th Patient

Retrieved on: 
Tuesday, October 24, 2023
Patient, Early, MD, Health, LCMC, Memorial Sloan Kettering Cancer Center, Oncology, Cancer, Pharmaceutical industry

NEW YORK, Oct. 24, 2023 /PRNewswire/ -- The Lung Cancer Mutation Consortium (LCMC), facilitated by the Lung Cancer Research Foundation (LCRF), announces the enrollment of one hundred patients in its fourth study, LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer (LEADER), examining targeted drugs given as single agents and combinations as neoadjuvant therapies matched to specific genetic mutations.

Key Points: 
  • NEW YORK, Oct. 24, 2023 /PRNewswire/ -- The Lung Cancer Mutation Consortium (LCMC), facilitated by the Lung Cancer Research Foundation (LCRF), announces the enrollment of one hundred patients in its fourth study, LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer (LEADER), examining targeted drugs given as single agents and combinations as neoadjuvant therapies matched to specific genetic mutations.
  • This is the first of the LEADER trial's major milestones to be met, with many more to come.
  • Patients with early-stage lung cancers who are interested in participating in the LCMC LEADER trial should discuss the study with their oncologist to determine eligibility and the process for enrollment.
  • To learn more about LCRF and its grants program, visit www.lcrf.org
    To learn more about LCMC and the LEADER trial, visit LCRF.org/LCMC4